0.93
price down icon7.92%   -0.08
after-market アフターアワーズ: .93
loading
前日終値:
$1.01
開ける:
$0.99
24時間の取引高:
208.39K
Relative Volume:
0.66
時価総額:
$20.06M
収益:
-
当期純損益:
$-8.29M
株価収益率:
-1.3286
EPS:
-0.7
ネットキャッシュフロー:
$-6.47M
1週間 パフォーマンス:
+9.41%
1か月 パフォーマンス:
-17.70%
6か月 パフォーマンス:
-39.61%
1年 パフォーマンス:
-33.57%
1日の値動き範囲:
Value
$0.93
$1.05
1週間の範囲:
Value
$0.88
$1.05
52週間の値動き範囲:
Value
$0.85
$2.2299

NanoViricides Inc Stock (NNVC) Company Profile

Name
名前
NanoViricides Inc
Name
セクター
Healthcare (1112)
Name
電話
203-937-6137
Name
住所
1 Controls Drive, Shelton, CT
Name
職員
7
Name
Twitter
@nnvcnyse
Name
次回の収益日
2025-12-03
Name
最新のSEC提出書
Name
NNVC's Discussions on Twitter

Compare NNVC vs VRTX, REGN, ARGX, ALNY, ONC

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
NNVC
NanoViricides Inc
0.93 21.78M 0 -8.29M -6.47M -0.70
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
465.02 117.03B 11.74B 3.68B 3.34B 14.19
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
783.65 82.35B 14.34B 4.50B 3.77B 41.56
Biotechnology icon
ARGX
Argen X Se Adr
833.54 51.64B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
308.48 42.58B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
ONC
Beone Medicines Ltd Adr
346.42 38.87B 4.98B 69.60M 525.67M 0.5198

NanoViricides Inc Stock (NNVC) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-12-16 開始されました Alliance Global Partners Buy
2015-02-11 開始されました Midtown Partners Strong Buy

NanoViricides Inc (NNVC) 最新ニュース

pulisher
10:30 AM

Small cap wrap: BioVie, VivoPower, NanoViricides, Aftermath Silver... - Proactive financial news

10:30 AM
pulisher
09:23 AM

NanoViricides seeks FDA orphan status for MPox drug - Proactive financial news

09:23 AM
pulisher
08:45 AM

MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides - Bitget

08:45 AM
pulisher
08:30 AM

New Mpox drug candidate NV-387 chases FDA orphan status - Stock Titan

08:30 AM
pulisher
07:38 AM

NanoViricides Files for Orphan Drug Status as U.S. Measles Cases Surge (MRNA,QNCX) - Barchart.com

07:38 AM
pulisher
Feb 10, 2026

Small cap wrap: Medicus Pharma, 1911 Gold, NanoViricides, Nextech3D.ai, NextSource Materials… - Proactive Investors

Feb 10, 2026
pulisher
Feb 10, 2026

Measles cases surge as NanoViricides seeks orphan status for NV-387 - Stock Titan

Feb 10, 2026
pulisher
Feb 10, 2026

NanoViricides seeks orphan drug status with US FDA for measles treatment - Proactive financial news

Feb 10, 2026
pulisher
Feb 09, 2026

NanoViricides President Dr. Diwan Interviewed by Mission Matters’ Adam Torres - USA Today

Feb 09, 2026
pulisher
Feb 07, 2026

Trading Recap: Is NanoViricides Inc part of any ETFJuly 2025 Drop Watch & Real-Time Buy Signal Alerts - baoquankhu1.vn

Feb 07, 2026
pulisher
Feb 05, 2026

CEO Change: Is NanoViricides Inc undervalued by DCF analysisWeekly Stock Recap & Safe Entry Zone Identification - baoquankhu1.vn

Feb 05, 2026
pulisher
Feb 03, 2026

NanoViricides President Discusses Broad-Spectrum Antiviral Platform and Upcoming Phase II Trial for MPox Treatment - citybuzz -

Feb 03, 2026
pulisher
Feb 02, 2026

NanoViricides Comments on the Need for Broad-Spectrum Antivirals in Light of the Current Influenza WaveNV-387 is Effective Against H3N2 - Enterprise News

Feb 02, 2026
pulisher
Feb 02, 2026

NanoViricides President Dr. Diwan Interviewed by Mission Matters' Adam Torres - accessnewswire.com

Feb 02, 2026
pulisher
Jan 29, 2026

Can NanoViricides Inc. continue delivering strong returnsJuly 2025 Momentum & Weekly Watchlist for Consistent Profits - mfd.ru

Jan 29, 2026
pulisher
Jan 28, 2026

Can NanoViricides Inc continue delivering strong returnsQuarterly Growth Report & Fast Exit and Entry Strategy Plans - baoquankhu1.vn

Jan 28, 2026
pulisher
Jan 24, 2026

NanoViricides, Inc. Has Filed its Quarterly ReportSubsequent Raise Has Fortified Fiscal Position - Hattiesburg American

Jan 24, 2026
pulisher
Jan 24, 2026

NanoViricides to Present at the 3rd Annual DealFlow Discovery Conference - chronicle-tribune.com

Jan 24, 2026
pulisher
Jan 23, 2026

NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close - hattiesburgamerican.com

Jan 23, 2026
pulisher
Jan 23, 2026

NanoViricides Has Signed a Master Services Agreement with OnlyOrphansCote Regarding Orphan Drug Strategy of NV-387 for Treatment of MPox, Smallpox, and Measles - Hattiesburg American

Jan 23, 2026
pulisher
Jan 22, 2026

ETF Watch: Should I hold or sell NanoViricides Inc nowJuly 2025 Chart Watch & AI Powered Market Entry Ideas - baoquankhu1.vn

Jan 22, 2026
pulisher
Jan 17, 2026

Aug Momentum: Is NanoViricides Inc forming a bullish divergenceTrade Analysis Summary & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn

Jan 17, 2026
pulisher
Jan 16, 2026

Support Test: Should I invest in NanoViricides Inc before earningsJuly 2025 PostEarnings & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn

Jan 16, 2026
pulisher
Jan 15, 2026

Jobs Data: How much upside does NanoViricides Inc have2025 Bull vs Bear & Long-Term Capital Growth Strategies - baoquankhu1.vn

Jan 15, 2026
pulisher
Jan 13, 2026

NanoViricides Highlights Need for Broad-Spectrum Antivirals During Severe Influenza Season - citybuzz -

Jan 13, 2026
pulisher
Jan 13, 2026

NanoViricides highlights need for broad-spectrum antivirals amid severe flu season - Proactive financial news

Jan 13, 2026
pulisher
Jan 13, 2026

San Gabriel Valley Tribune - FinancialContent

Jan 13, 2026
pulisher
Jan 13, 2026

Options Flow: Will NanoViricides Inc. stock continue dividend increases2025 Winners & Losers & Short-Term Swing Trade Alerts - Bộ Nội Vụ

Jan 13, 2026
pulisher
Jan 12, 2026

Market Recap: Can NanoViricides Inc NV3P stock sustain institutional flowsInflation Watch & Stock Portfolio Risk Control - Bộ Nội Vụ

Jan 12, 2026
pulisher
Jan 11, 2026

After-Hours Rally: Zentalis, LifeMD, And NanoViricides Among Top Gainers - Nasdaq

Jan 11, 2026
pulisher
Jan 10, 2026

Published on: 2026-01-10 19:47:32 - ulpravda.ru

Jan 10, 2026
pulisher
Jan 10, 2026

Volume Summary: Will NanoViricides Inc NV3P stock outperform small cap peersJuly 2025 Chart Watch & Reliable Breakout Forecasts - moha.gov.vn

Jan 10, 2026
pulisher
Jan 10, 2026

NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo - patriotledger.com

Jan 10, 2026
pulisher
Jan 10, 2026

Can NanoViricides Inc. stock outperform in 2025 bull marketJuly 2025 Weekly Recap & Reliable Price Action Trade Plans - Улправда

Jan 10, 2026
pulisher
Jan 09, 2026

Can NanoViricides Inc. stock hit record highs againPortfolio Update Summary & Expert Curated Trade Setup Alerts - Улправда

Jan 09, 2026

NanoViricides Inc (NNVC) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$44.80
price up icon 1.24%
$26.75
price down icon 0.19%
$100.75
price up icon 1.93%
$105.76
price down icon 3.31%
$146.17
price down icon 1.52%
biotechnology ONC
$346.42
price down icon 1.38%
大文字化:     |  ボリューム (24 時間):